Avience Biomedicals came to market through an SME IPO that opened on 18 June 2026 and closed on 22 June 2026, and the shares listed on 25 June 2026 on NSE SME. The price band was ₹196 to ₹208 per share and one lot was 600 shares, so the minimum application was ₹1,24,800. The issue size was ₹30.24 crore. The whole issue was fresh shares, so the money raised went to the company.
Skyline Financial Services Pvt.Ltd was the registrar to the issue, and Fintellectual Corporate Advisors Pvt.Ltd was the lead manager.
As of 22 June 2026.
| Day |
|---|
| 1 |
| 2 |
| 3 |
Incorporatedin June 2024, Avience Biomedicals Limited is an ISO-certified company involved in the manufacture, supply, and export of molecular diagnostics solutions, with an emphasis on biotechnology, genomics, and the IVD sector. Avience Biomedicals Limited has diversified its portfolio of products from IVD rapid test kits to include an extensive range of medical devices such as serology products and biochemistry analyzers.
It is committed to addressing varied healthcare needs with a special focus only on the B2B and B2G markets.The products of the company are targeted at Pathology Labs, Microbiology Labs, Hospitals, and Research Centers both in the nation and abroad. Besides being a manufacturer, the Company also acts as a distributor and trader of medical equipment.The company's manufacturing plant is located in Noida, Uttar Pradesh. As of January 31, 2026, the company has 75 permanent employees and 33 contractual employees.
As described in the offer document.
| Metric | 31-Jan-26 | 31-Mar-25 | 31-Mar-24 |
|---|
Avience Biomedicals Limited finalised its anchor investor allocation on June 17, 2026, raising ₹8.52 crore from 4 institutional investors at an anchor price of ₹208 per share. The anchor book comprises 4,09,800 equity shares allocated across non-mutual fund institutional investors. Sanshi Fund-I received the largest allocation at 35.29%, followed by Meru Investment Fund PCC – Cell 1 at 29.43% and Fortune Hands Growth Fund Scheme I at 23.43%.
Shine Star Build Cap Pvt Ltd received the remaining 11.86% of the anchor portion
Mr. Dharam Deo Choudhary, Mr. Ram Nagina Choudhary, Mr. Janardan Pal, Ms. Deepa Choudhary. Promoter holding 87.89% before the issue and 64.59% after.
Work out the listing gain for this SME IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Avience Biomedicals IPO was a ₹30.24 crore book-built issue, made up entirely of a fresh issue. It was priced at ₹196–₹208 per share with a lot size of 600 shares; the minimum retail application was 1,200 shares (₹2,49,600). The IPO was open from June 18 to June 22, 2026 and was subscribed 385.33x. Shares listed on NSE SME on June 25, 2026 at ₹395.20, a 90.0% premium to the issue price of ₹208. Skyline Financial Services Pvt. Ltd.
is the registrar. Fintellectual Corporate Advisors Pvt. Ltd. is the book running lead manager.
The price band of Avience Biomedicals IPO is ₹196 to ₹208 per share.
The lot size of Avience Biomedicals IPO is 600 shares.
The minimum investment for Avience Biomedicals IPO is approximately ₹2,49,600 based on the upper price band.
The allotment date of Avience Biomedicals IPO is Jun 23, 2026.
Avience Biomedicals IPO's final recorded GMP before listing was ₹100 per share (a 48% premium over the ₹208 upper price band). The shares listed at ₹395.2. GMP is unofficial and does not forecast or guarantee the actual listing price.
You can check Avience Biomedicals IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Avience Biomedicals IPO allotment status on Rupix for quick and easy access.
₹196 to ₹208 per share, against a face value of ₹10. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 600 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹1,24,800. After listing, SME shares also trade in lots rather than one share at a time.
₹1,24,800, for one lot of 600 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 18 June 2026 and closed on 22 June 2026.
The basis of allotment was published on 23 June 2026 by Skyline Financial Services Pvt.Ltd, and allotted shares were credited to demat accounts before listing.
The shares listed on 25 June 2026 on NSE SME.
The issue size was ₹30.24 crore. The fresh issue was 14,53,800 shares (aggregating up to ₹30.24 crore).